Paul H Yoshihara

20070031451, Feb 8, 2007

Aug 7, 2006

11/500763

Mark Slifka - Portland OR, US
Shirley Carter - Lake Oswego OR, US
Erika Hammarlund - Hillsboro OR, US
Paul Yoshihara - Portland OR, US

A61K 39/12
A61K 39/02
A61K 33/40

424204100, 424234100, 424616000

The present disclosure provides methods for producing a vaccine composition containing a pathogen that is rendered noninfectious by exposure to hydrogen peroxide. The methods disclosed herein are suitable for the preparation of vaccines for a wide variety of pathogens, including viruses, bacteria and parasites. The disclosure also provides vaccine compositions (medicaments) containing a pathogen inactivated by exposure to hydrogen peroxide. Methods for eliciting an immune response in a subject by administering vaccine compositions containing a hydrogen peroxide inactivated pathogen are also provided.

20100316653, Dec 16, 2010

Jun 13, 2005

11/629417

Mark Slifka - Portland OR, US
Paul Yoshihara - Portland OR, US
Erika Hammarlund - Hillsboro OR, US

Oregon Health & Science University - Portland OR

A61K 39/42
C12Q 1/70
C40B 30/04
C40B 40/10
C07K 16/08

4241591, 435 5, 506 9, 506 18, 5303871, 5303873, 5303883

In particular aspects, the invention provides a novel approach for the systematic analysis and identification of biologically relevant epitopes (SABRE). SABRE-identified polypeptides have diagnostic (e.g., polypeptide arrays, etc.) and/or therapeutic (e.g., vaccines, etc.) utility, and utility for developing monoclonal antibodies having diagnostic and/or therapeutic utility (e.g. for detecting and/or preventing orthopoxvirus infection). Preferred aspects provide high-throughput assays for detecting specific orthopoxvirus infection, for detecting orthopoxvirus-specific immune response, or for dual (parallel) determination of both orthopoxvirus immune response and orthopoxvirus infection. Additional preferred and surprising aspects provide novel high-throughput methods for detecting ‘protective immunity’ against orthopoxviruses (e.g., for detecting protective immunity against smallpox virus and monkeypox virus), based on anti-vaccinia virus serum antibody levels. The inventive diagnostic assays are rapid, high-throughput and suitable for ‘point-of-care’ implementations.

20130004525, Jan 3, 2013

Feb 24, 2012

13/405082

Mark K. Slifka - Banks OR, US
Shirley Villadiego - Miami FL, US
Erika Hammarlund - Hillsboro OR, US
Paul Yoshihara - Portland OR, US

Oregon Health and Science University - Portland OR

A61K 39/00
A61P 37/04

4241841

The present disclosure provides methods for producing a vaccine composition containing a pathogen that is rendered noninfectious by exposure to hydrogen peroxide. The methods disclosed herein are suitable for the preparation of vaccines for a wide variety of pathogens, including viruses, bacteria and parasites. The disclosure also provides vaccine compositions (medicaments) containing a pathogen inactivated by exposure to hydrogen peroxide. Methods for eliciting an immune response in a subject by administering vaccine compositions containing a hydrogen peroxide inactivated pathogen are also provided.

20140242115, Aug 28, 2014

May 5, 2014

14/269708

- Portland OR, US
Shirley Villadiego - Miami FL, US
Erika Hammarlund - Hillsboro OR, US
Paul Yoshihara - Portland OR, US

Oregon Health and Science University - Portland OR

A61K 39/285

4242321

The present disclosure provides methods for producing a vaccine composition containing a pathogen that is rendered noninfectious by exposure to hydrogen peroxide. The methods disclosed herein are suitable for the preparation of vaccines for a wide variety of pathogens, including viruses, bacteria and parasites. The disclosure also provides vaccine compositions (medicaments) containing a pathogen inactivated by exposure to hydrogen peroxide. Methods for eliciting an immune response in a subject by administering vaccine compositions containing a hydrogen peroxide inactivated pathogen are also provided.